Publications

The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market

Ricardo Titze-de-Almeida, Catherine David & Simoneide Souza Titze-de-Almeida. Pharmaceutical Research. 2017. “KRAS-LODER made KRAS a druggable anticancer target. New drugs also targeting this oncogene are now in test and may represent future competitors of KRAS-LODER. KRAS-LODER is the only RNAi-based drug that provides a sustained release of siRNA into the tumor

Read More »

Pancreas adenocarcinoma: novel therapeutics

Benjamin A. Krantz, Kenneth H. Yu, Eileen M. O’Reilly. Chinese Clinical Oncology. 2017. “Targeting RAS by inhibiting translation using small-interfering RNAs is a novel strategy to decrease RAS activity. siRNA against the G12D mutant RAS RNA by local prolonged delivery, KRAS-LODER (Local Drug EluteR), has demonstrated decreased growth of human pancreatic

Read More »

Silenseed Phase II pancreatic cancer drug trial to begin

Israeli drug development company Silenseed is to begin a Phase II multicenter trial for its pancreatic cancer treatment. The study, which has been approved by the US Food and Drug Administration (FDA), will be held at several leading medical centers in the US with the participation of 80 patients. At

Read More »